Pyrazolo[1,5-a]Pyrimidine-7-Amine CDK9 Inhibitors With Selective Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CDK9 inhibitors lack high inhibitory activity, selectivity, and improved in vivo pharmacokinetic parameters, necessitating the development of new compounds to effectively target CDK9-mediated diseases.
Innovation Solution
Development of substituted pyrazolo[1,5-a]pyrimidin-7-amine derivatives with high CDK9 inhibitory activity and selectivity, designed to inhibit CDK9 activity and promote apoptosis in tumor cells, thereby treating hyperproliferative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CDK9 inhibitors are used, then some inhibitory activity is achieved, but the inhibitory activity and selectivity are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical parameters of the pyrazolo[1,5-a]pyrimidine core structure, including substituting hydrogen atoms at specific positions (R1-R6) with various functional groups and modifying the heterocyclic ring system. This structural parameter optimization resulted in compounds with enhanced CDK9 inhibitory activity and selectivity, directly resolving the technical contradiction between achieving sufficient inhibitory activity and maintaining development efficiency.
Solution Approach 2:
The patent employs composite material principles by creating hybrid molecular structures that combine the pyrazolo[1,5-a]pyrimidine core with diverse substituent groups and heterocyclic moieties. This composite approach allows the molecule to integrate multiple functional characteristics, achieving both high CDK9 inhibitory activity and improved pharmacokinetic properties simultaneously.
2Reliability
If existing CDK9 inhibitors are developed, then early stage clinical development is achieved, but in vivo pharmacokinetic parameters need improvement
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and heterocyclic structures at particular positions of the molecular framework. By strategically placing these structural elements at key locations (such as positions R1-R6 on the pyrazolo[1,5-a]pyrimidine core), the compound achieves optimized pharmacokinetic properties including improved bioavailability and metabolism, while maintaining manageable molecular complexity.
Solution Approach 2:
The patent utilizes parameter changes by adjusting molecular weight, logP values, and other pharmacokinetic-related parameters through systematic structural modification. These parameter optimizations enabled the compounds to achieve favorable in vivo pharmacokinetic profiles, resolving the contradiction between improving pharmacokinetic parameters and avoiding excessive molecular complexity.
3Reliability
If CDK9 inhibitors are developed to treat hyperproliferative diseases, then therapeutic effectiveness is improved, but toxicity may increase
Solution Approach 1:
The patent applies parameter changes by optimizing the balance between potency and selectivity through structural modification. By carefully selecting substituents and heterocyclic groups, the compound achieves high CDK9 inhibitory activity while maintaining selectivity that reduces off-target effects and toxicity. This parameter optimization enabled therapeutic effectiveness in treating hyperproliferative diseases without excessive toxicity.
Solution Approach 2:
The patent employs local quality by introducing specific functional groups that enhance CDK9 binding affinity while simultaneously improving selectivity over other kinases. This localized structural optimization at key positions of the molecule resulted in improved therapeutic index, effectively treating diseases while minimizing harmful effects on normal tissues.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A substituted pyrazolo[1,5-alpyrimidin-7-amine derivative, the structure of which is represented by formula (l), or pharmaceutically acceptable salts, solvates, stereoisomers, prodrugs, drug compositions thereof. The derivative has significant CDK9-selective inhibitory activity.